Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

AG-MONTELUKAST - Health Canada Drug Approval Details

Approvals/Health Canada/AG-MONTELUKAST

Authorized

STANDARD

AG-MONTELUKAST

angita pharma inc.🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: 39aa5dae20c5f8dd
Company: angita pharma inc.
Type: Standard

Approval Details

Approval Id: 39aa5dae20c5f8dd
Drug Approval Canada Name: AG-MONTELUKAST
Product Name: AG-MONTELUKAST
Status: Marketed
Status Date: 2022-12-29
Original Market Date: 2019-12-10
Din: 02482835
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 48:10.24
Atc Original: R03DC03 MONTELUKAST
Atc Name: r 03 dc 03
Aig Number: 0133823002
Company Name: angita pharma inc.
Company Address: 1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3

Active Ingredients

MONTELUKAST (MONTELUKAST SODIUM)

10 MG

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

39aa5dae20c5f8dd

Type

Standard

Back to Health Canada Approvals